Browse > Article

Safety and Pharmacokinetics of Theobromine after Multiple Adminstrations in Healthy Volunteers  

Kim, Jung-Won (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Shin, Kwang-Hee (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Yi, So-Jeong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Kim, Tae-Eun (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Oh, Se-Ul (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Yoon, Seo-Hyun (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Cho, Joo-Youn (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Shin, Sang-Goo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Publication Information
Journal of Korean Society for Clinical Pharmacology and Therapeutics / v.18, no.1, 2010 , pp. 15-22 More about this Journal
Abstract
Background: Theobromine (3,7-dimethylxanthine) has various clinical properties including vasodilation, bronchodilation, and diuresis in humans. It is currently under clinical investigation for cough suppression. The aim of this study was to evaluate the safety and pharmacokinetic characteristics after multiple oral administrations of theobromine 500 mg capsules in healthy male volunteers. Methods: A single-arm, multiple-dosing study was conducted in 12 healthy male volunteers. All subjects orally received the study drug every 12 hours for 7 days. Blood samples were collected up to 12 hours after first dosing and up to 48 hours after last dosing. Plasma concentrations of theobromine were analyzed using high-performance liquid chromatography. Safety assessments, including monitoring adverse events, laboratory tests, vital signs, ECGs, and physical examinations, were performed throughout the study. Results: Pharmacokinetic steady-state was achieved before the last dosing. Median time to peak concentration at steady state ($T_{max,ss}$) was 1.8 hr. Mean terminal half-life was 13.4 hr, and mean peak-trough fluctuation was 47.5% at steady state. At steady state, mean peak concentration ($C_{max,ss}$) and area under the plasma concentration-time curve during a dosing interval ($AUC_{\tau,ss}$) was $22.0\;{\mu}g/mL$ (coefficient of variation, CV: 13.8%) and $213.9\;{\mu}g{\ast}h/mL$ (CV: 17.6%), respectively. Mean accumulation ratio ranged from 1.8 to 2.8 after multiple administrations. There were neither any serious adverse events nor remarkable findings regarding safety. Conclusion: Theobromine capsules were safe and well-tolerated when administered twice daily at dose of 500 mg for 7 days. This study showed the relatively low inter-individual variation in terms of $C_{max}$ and AUC, and moderate accumulation after multiple dosing. This study provided evidence for a twice-a-day dosing regimen of theobromine 500 mg capsules for treatment of chronic cough.
Keywords
Theobromine capsule; Antitussives; Pharmacokinetics; Multiple administration; Cough;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 THOMSON. MICROMEDEX. Available at:http://ccis.snuh.org/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/518271/DUPLICATIONSHIELDSYNC/94D102/ND_PG/PRIH/ND_B/HCS/SBK/2/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/0012/ContentSetId/31/SearchTerm/theophylline%20/SearchOption/BeginWith.
2 KORBONITS D, ARaNYI P, JELINEK I, MIKUS E. ANTITUSSIVE COMPOSITIONS, WO/1998/042322, 1997.
3 Pavesi L, Subburaj S, Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest, 2001;120(4):1121-1128.   DOI   ScienceOn
4 Resine T, and Pasternak, G. Goodman and Gilman's the pharmacological basis of therapeutics, 6th ed.; 1996.
5 Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am Rev Respir Dis, 1990;141(3):640-647.   DOI
6 Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA, Korbonits M, Korbonits D, Barnes PJ. Theobromine inhibits sensory nerve activation and cough. FASEB J, 2005;19(2):231-233.
7 Dicpinigaitis PV. Currently available antitussives. Pulm Pharmacol Ther, 2009;22(2):148-151.   DOI   ScienceOn
8 Cho SH. Cough. The Korean Journal of Medicine, 2009;76(3):252-259.